PLX - Protalix BioTherapeutics, Inc Long-Term Liabilities to Capital

Protalix BioTherapeutics (PLX) revenues rely on a single drug for Fabry disease, which is offset by a global partnership. The brand's high authority in developing plant-based proteins for the therapy of rare pathologies is confirmed by the current share prices shown on the GURU.Markets chart, where the indicator stands at 0.12. Business efficiency is bolstered by the ability to produce medications on an industrial scale via bioreactors, eliminating costly animal components.

Financial autonomy during pipeline development is critical for the biotechnology sector with niche innovations in protein expression. This metric compares obligations with maturities exceeding one year against equity to determine the extent of Protalix BioTherapeutics (PLX) reliance on debt financing. By analyzing the long-term debt-to-equity ratio trend, an investor assesses the resilience of the business model and the company's ability to maintain technical processes without excessive credit pressure.